Across TCGA pan-cancer cohorts, ERVMER34-1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ERVMER34-1 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ERVMER34-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ERVMER34-1 expression acts as an unfavorable survival marker.

SARC and UCEC are the cancer types where ERVMER34-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.109	0.827	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ERVMER34-1 tumor-vs-normal RNA expression · all ERVMER34-1 data types